The importance of ER and HER2 activation to breast cancer growth is underlined by improved outcome for patients with advanced ER+ and HER2 amplified early breast cancers treated with an aromatase inhibitor and anti-HER2 therapy in concert [2,3]. The gene discussed is CYP19A1; the disease is breast cancer.